These data demonstrated that the rare mutational burden of DPYS—a gene that cooperates closely with DPYD in the catabolic pathway of FLs—is another promising pharmacogenetic marker for precision dosing of FL, which may improve treatment personalization, especially in cancer patients with normal DPD activity. Here, DPYD is linked to cancer.